Article citationsMore>>

Demaria, O., Carvelli, J., Batista, L., Thibult, M.L., Morel, A. andre, P., Morel, Y., Vely, F. and Vivier, E. (2020) Identification of Druggable Inhibitory Immune Checkpoints on Natural Killer Cells in COVID-19. Cellular & Molecular Immunology, 17, 995-997.
https://doi.org/10.1038/s41423-020-0493-9

has been cited by the following article:

• TITLE: SARS-COV-2 Induce Pulmonary Injury from Basic to Clinical Research

  AUTHORS: Jinguo Zhu

  KEYWORDS: COVID-19, SARS-CoV-2, Pulmonary Injury, Clinical Manifestation, Treatment Strategies

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.12 No.3, March 31, 2022

  ABSTRACT: The SARS-CoV-2 has infected over 194,909,000 cases and over 4,170,000 deaths in the world before the end of July 2021. The virus attacks human alveoli and induces severe lung injury (COVID-19 disease) and spreads rapidly. The mechanisms of COVID-19 disease are unclear. To better understand this disease, This review analyzes the SARS-CoV-2 biological characteristics, insights the effect of alveolar epithelium and its adjacent microvascular endothelium, investigates human host cells immune response and immunothrombosis. Explains clinical manifestations of COVID-19 associated lung injury. It may be helpful for development management strategies for COVID-19 associated pulmonary damage.